DK3360538T3 - Injicerbar, flydende sammensætning omfattende buprenorphin - Google Patents

Injicerbar, flydende sammensætning omfattende buprenorphin Download PDF

Info

Publication number
DK3360538T3
DK3360538T3 DK17205986.7T DK17205986T DK3360538T3 DK 3360538 T3 DK3360538 T3 DK 3360538T3 DK 17205986 T DK17205986 T DK 17205986T DK 3360538 T3 DK3360538 T3 DK 3360538T3
Authority
DK
Denmark
Prior art keywords
buprenorphine
liquid composition
injectable liquid
injectable
composition
Prior art date
Application number
DK17205986.7T
Other languages
Danish (da)
English (en)
Inventor
Richard L Norton
Andrew Watkins
Mingxing Zhou
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3360538(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Application granted granted Critical
Publication of DK3360538T3 publication Critical patent/DK3360538T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17205986.7T 2010-06-08 2011-06-06 Injicerbar, flydende sammensætning omfattende buprenorphin DK3360538T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
EP11728037.0A EP2579874B1 (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine

Publications (1)

Publication Number Publication Date
DK3360538T3 true DK3360538T3 (da) 2023-03-06

Family

ID=42471306

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17205986.7T DK3360538T3 (da) 2010-06-08 2011-06-06 Injicerbar, flydende sammensætning omfattende buprenorphin
DK11728037.0T DK2579874T3 (da) 2010-06-08 2011-06-06 Injicerbar, flydende sammensætning omfattende buprenorphin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11728037.0T DK2579874T3 (da) 2010-06-08 2011-06-06 Injicerbar, flydende sammensætning omfattende buprenorphin

Country Status (32)

Country Link
US (1) US8921387B2 (cg-RX-API-DMAC7.html)
EP (3) EP2579874B1 (cg-RX-API-DMAC7.html)
JP (2) JP5986072B2 (cg-RX-API-DMAC7.html)
KR (1) KR101865689B1 (cg-RX-API-DMAC7.html)
CN (1) CN103079544B (cg-RX-API-DMAC7.html)
AU (1) AU2011263478B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012031290A2 (cg-RX-API-DMAC7.html)
CA (1) CA2801676C (cg-RX-API-DMAC7.html)
CL (1) CL2012003462A1 (cg-RX-API-DMAC7.html)
CO (1) CO6670529A2 (cg-RX-API-DMAC7.html)
CY (1) CY1120761T1 (cg-RX-API-DMAC7.html)
DK (2) DK3360538T3 (cg-RX-API-DMAC7.html)
ES (2) ES2939612T3 (cg-RX-API-DMAC7.html)
FI (1) FI3360538T3 (cg-RX-API-DMAC7.html)
GB (2) GB2513267B (cg-RX-API-DMAC7.html)
HR (1) HRP20180118T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038275T2 (cg-RX-API-DMAC7.html)
IL (2) IL223488A (cg-RX-API-DMAC7.html)
LT (1) LT2579874T (cg-RX-API-DMAC7.html)
MX (1) MX339209B (cg-RX-API-DMAC7.html)
MY (1) MY171625A (cg-RX-API-DMAC7.html)
NO (1) NO2579874T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ604026A (cg-RX-API-DMAC7.html)
PL (1) PL2579874T3 (cg-RX-API-DMAC7.html)
PT (1) PT2579874T (cg-RX-API-DMAC7.html)
RS (1) RS56820B1 (cg-RX-API-DMAC7.html)
RU (1) RU2607498C2 (cg-RX-API-DMAC7.html)
SG (1) SG186200A1 (cg-RX-API-DMAC7.html)
SI (1) SI2579874T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800038T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011154724A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201209233B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
CH708257B1 (de) 2012-04-17 2019-05-15 Purdue Pharma Lp Zusammensetzung zur Behandlung einer Opioid-induzierten unerwünschten pharmakodynamischen Reaktion.
ES2837803T3 (es) 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
EP2877155B1 (en) * 2012-07-26 2020-10-28 Camurus AB Opioid formulations
US20150320866A1 (en) * 2012-12-13 2015-11-12 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
KR102370470B1 (ko) * 2013-03-15 2022-03-04 헤론 테라퓨틱스 인코포레이티드 폴리오르토에스테르 및 비프로톤성 용매의 조성물
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
HUE055973T2 (hu) 2014-04-21 2022-01-28 Heron Therapeutics Inc Hosszanható polimerikus célba juttató rendszerek
US11083730B2 (en) 2014-04-21 2021-08-10 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
HRP20202010T1 (hr) * 2014-04-21 2021-03-05 Heron Therapeutics, Inc. Pripravci poliortoestera i organska kiselina kao pomoćna tvar
CA2945181C (en) 2014-04-28 2022-10-18 Orphomed, Inc. Pharmaceutically active dimers linked through phenolic hydroxyl groups
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
WO2016071767A1 (en) * 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
BR112018002414B1 (pt) 2015-08-03 2023-11-21 Tolmar International Limited Composição farmacêutica de polímero líquido para administração no corpo de um animal, seu uso para tratar, prover uma terapia para curar ou prevenir uma doença, distúrbio ou outra enfermidade e sistema de distribuição para administração da dita composição
KR102766991B1 (ko) 2015-11-16 2025-02-13 메딘셀 에스.에이. 활액 조직에 약제학적으로 활성인 유효성분을 모셀라이징 및/또는 표적화하는 방법
CA3033046C (en) 2016-09-13 2021-09-07 Alar Pharmaceuticals Inc. Sustained-release buprenorphine formulations
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
EP3638240A2 (en) 2017-06-16 2020-04-22 Indivior UK Limited Methods to treat opioid use disorder
AU2019209416A1 (en) 2018-01-22 2020-07-30 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
BR112020016576A2 (pt) 2018-05-11 2020-12-15 Alar Pharmaceuticals Inc. Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina
AU2019357036B2 (en) 2018-10-11 2024-11-14 Indivior Uk Limited Buprenorphine to treat respiratory depression
US12403291B2 (en) * 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CN118831057A (zh) * 2023-04-25 2024-10-25 深圳善康医药科技股份有限公司 丁丙诺啡植入剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
CA2187353C (en) 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
AU2003240493B2 (en) * 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
KR20050088288A (ko) * 2002-11-06 2005-09-05 알자 코포레이션 제어식 방출 데포 제형
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
EP1804751A2 (en) * 2004-10-04 2007-07-11 QLT USA, Inc. Ocular delivery of polymeric delivery formulations
PT1824460E (pt) * 2004-11-10 2015-01-14 Tolmar Therapeutics Inc Um sistema de administração polimérico estabilizado
PT2115029E (pt) 2007-02-15 2015-10-26 Tolmar Therapeutics Inc Poli-(lactido/glicolido) de efeito de libertação imediata reduzido e métodos de produção de polímeros
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
WO2011154724A3 (en) 2012-07-12
EP3360538A1 (en) 2018-08-15
EP2579874A2 (en) 2013-04-17
AU2011263478B2 (en) 2015-01-22
JP2013533230A (ja) 2013-08-22
CN103079544A (zh) 2013-05-01
CA2801676A1 (en) 2011-12-15
CL2012003462A1 (es) 2013-04-01
MY171625A (en) 2019-10-21
JP6251774B2 (ja) 2017-12-20
CA2801676C (en) 2018-08-07
ES2939612T3 (es) 2023-04-25
AU2011263478A1 (en) 2013-01-10
PL2579874T3 (pl) 2018-05-30
LT2579874T (lt) 2018-02-12
MX2012014335A (es) 2013-03-05
WO2011154724A2 (en) 2011-12-15
JP5986072B2 (ja) 2016-09-06
CO6670529A2 (es) 2013-05-15
IL254417A0 (en) 2017-11-30
NZ604026A (en) 2015-01-30
HRP20180118T1 (hr) 2018-03-09
WO2011154724A9 (en) 2012-08-16
US20130210853A1 (en) 2013-08-15
GB201009549D0 (en) 2010-07-21
FI3360538T3 (fi) 2023-03-22
NO2579874T3 (cg-RX-API-DMAC7.html) 2018-06-09
HUE038275T2 (hu) 2018-10-29
MX339209B (es) 2016-04-15
BR112012031290A2 (pt) 2016-11-01
ZA201209233B (en) 2014-04-30
RS56820B1 (sr) 2018-04-30
US8921387B2 (en) 2014-12-30
GB2513267B (en) 2015-03-18
KR101865689B1 (ko) 2018-06-08
CN103079544B (zh) 2017-06-09
KR20130135026A (ko) 2013-12-10
SI2579874T1 (en) 2018-03-30
EP4218720A1 (en) 2023-08-02
RU2012157244A (ru) 2014-07-20
PT2579874T (pt) 2018-01-29
GB2513267A (en) 2014-10-22
GB2481018A (en) 2011-12-14
SG186200A1 (en) 2013-01-30
DK2579874T3 (da) 2018-01-29
RU2607498C2 (ru) 2017-01-10
JP2016155865A (ja) 2016-09-01
ES2656938T3 (es) 2018-03-01
IL223488A (en) 2017-10-31
GB2481018B (en) 2015-03-18
EP3360538B1 (en) 2023-02-15
SMT201800038T1 (it) 2018-03-08
EP2579874B1 (en) 2018-01-10
CY1120761T1 (el) 2019-12-11
GB201413064D0 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
DK3360538T3 (da) Injicerbar, flydende sammensætning omfattende buprenorphin
DK3257890T3 (da) Tværbindelig sammensætning
SMT201700008B (it) Composizione farmaceutica
BR112012031667A2 (pt) composição
EP2526922A4 (en) Viscous composition
PT2593094T (pt) Composição aquosa contendo bromexina
DK3246018T3 (da) Farmaceutisk sammensætning
BR112013022112A2 (pt) composição
BR112013022102A2 (pt) composição
BR112013016037A2 (pt) composição em gel.
DK2686017T3 (da) Oftalmisk sammensætning
BR112014004395A2 (pt) composição
BR112012032683A2 (pt) composição
EP2522643A4 (en) CONCRETE COMPOSITION
EE201300005A (et) Ravimkoostis
EP2636704A4 (en) FILM FORMING COMPOSITION
LT2865271T (lt) Pagerinta kompozicija
BR112013014204A2 (pt) composições de sucops espumantes
EA201201176A1 (ru) Битумная композиция
BR112012032980A2 (pt) composição
EP2628769A4 (en) FILM FORMING COMPOSITION
EP2548563A4 (en) ANTIALLERGIC COMPOSITION
BR112013033808A2 (pt) composição
PL2635269T3 (pl) Kompozycja złożona
DK2553004T3 (da) Sammensatte materialer